In FY2018, our first in human trial of PEN-866, a novel HSP90 inhibitor-SN38 drug conjugate, continued enrolling patients. The rationale for this study was based in part on preclinical work done in our lab demonstrating superior activity of PEN-866, as compared to other standard of care chemotherapy in models of pediatric sarcoma. Notably, the activity of PEN-866 was most durable in pediatric sarcoma models. For this reason, the ongoing clinical trial incorporates disease-specific expansion cohorts, including one for rhabdomyosarcoma and Ewing sarcoma, to include patients with these rare tumors. In the lab, we have continued to study PEN-866 in Ewing sarcoma and rhabdomyosarcoma, with a focus on identifying potential mechanisms of resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011774-02
Application #
9780061
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code